Please assess the completion status of the following clinical trial:

Trial Title: The Feasibility of Florbetapir Quantitation in Europe

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Readers have undergone Amyvid reader training~* Readers have not more than minimal experience with quantitation of amyloid PET scans~Exclusion Criteria:~* Readers have previously been trained to quantitate amyloid PET scans

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Physician Readers (Type: EXPERIMENTAL): Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir(18F) as part of this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).